Abstract
In search of novel cytotoxic agents based on acridone scaffold, twenty five derivatives of acridone-2- carboxamide were synthesized and evaluated against a panel of eleven cancer cell lines by using MTT assay. Amides, A5 and A8 (IC50 = 0.3 µM) exhibited good cytotoxicity against MCF7. Compound A22 (IC50 = 4.3 µM) was found to be selectively cytotoxic against cancer cell line MCF7 and KB403. Particularly, promising cytotoxic activities were shown by amides A6 (IC50 = 0.7 µM), A16 (IC50 = 6.3 µM), A8 (IC50 = 0.9 µM ), A21 (IC50 = 1.3 µM), A5 (IC50 = 2.9 µM), A8 (IC50 = 2.8 µM), A14 (IC50 = 0.8 µM), A9 (IC50 = 0.8 µM) and A8 (IC50 = 0.4 µM) against cell lines; PA1, WRL68, CaCO2, TK-10, K-562, PC-3, HOP-92, ECV-304 and UACC-257, respectively. The favorable cytotoxic profile and non-toxicity towards normal human cells displayed by the derivative revealed their potential for further anticancer drug developments.
Keywords: Acridone amides, anticancer, cytotoxicity, MTT assay, tricyclic compounds.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Synthesis of Novel Amides Based on Acridone Scaffold with Interesting Antineoplastic Activity
Volume: 15 Issue: 5
Author(s): Anand A. Mahajan, Rajesh A. Rane, Anish A. Amritkar, Shital S. Naphade, Pankaj B. Miniyar, Pavan Kumar Bangalore and Rajshekhar Karpoormath
Affiliation:
Keywords: Acridone amides, anticancer, cytotoxicity, MTT assay, tricyclic compounds.
Abstract: In search of novel cytotoxic agents based on acridone scaffold, twenty five derivatives of acridone-2- carboxamide were synthesized and evaluated against a panel of eleven cancer cell lines by using MTT assay. Amides, A5 and A8 (IC50 = 0.3 µM) exhibited good cytotoxicity against MCF7. Compound A22 (IC50 = 4.3 µM) was found to be selectively cytotoxic against cancer cell line MCF7 and KB403. Particularly, promising cytotoxic activities were shown by amides A6 (IC50 = 0.7 µM), A16 (IC50 = 6.3 µM), A8 (IC50 = 0.9 µM ), A21 (IC50 = 1.3 µM), A5 (IC50 = 2.9 µM), A8 (IC50 = 2.8 µM), A14 (IC50 = 0.8 µM), A9 (IC50 = 0.8 µM) and A8 (IC50 = 0.4 µM) against cell lines; PA1, WRL68, CaCO2, TK-10, K-562, PC-3, HOP-92, ECV-304 and UACC-257, respectively. The favorable cytotoxic profile and non-toxicity towards normal human cells displayed by the derivative revealed their potential for further anticancer drug developments.
Export Options
About this article
Cite this article as:
Mahajan A. Anand, Rane A. Rajesh, Amritkar A. Anish, Naphade S. Shital, Miniyar B. Pankaj, Bangalore Kumar Pavan and Karpoormath Rajshekhar, Synthesis of Novel Amides Based on Acridone Scaffold with Interesting Antineoplastic Activity, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (5) . https://dx.doi.org/10.2174/1871520614666141130130130
DOI https://dx.doi.org/10.2174/1871520614666141130130130 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanoparticle- and Liposome-carried Drugs: New Strategies for Active Targeting and Drug Delivery Across Blood-brain Barrier
Current Drug Metabolism HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Inflammatory Network
Inflammation & Allergy - Drug Targets (Discontinued) Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application
Current Vascular Pharmacology Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry Therapeutic Monoclonal Antibodies in Clinical Practice against Cancer
Anti-Cancer Agents in Medicinal Chemistry Acyclonucleosides, Modified Seco-Nucleosides, and Salicyl- or Catechol- Derived Acyclic 5-Fluorouracil O,N-Acetals: Antiproliferative Activities, Cellular Differentiation and Apoptosis
Current Medicinal Chemistry Pro-Inflammatory Mechanisms in Diabetic Neuropathy: Focus on the Nuclear Factor Kappa B Pathway
Current Drug Targets Circulating Levels of Angiogenic Cytokines in Waldenstrom’s Macroglobulinemia: Clinical Correlations
Current Angiogenesis (Discontinued) Aryl Hydrocarbon Receptor: Its Regulation and Roles in Transformation and Tumorigenesis
Current Drug Targets Combining Drug-Loaded Nanobubbles and Extracorporeal Shock Waves for Difficult-to-Treat Cancers
Current Drug Delivery Dendrimers as Novel Systems for Delivery of Neuropharmaceuticals to the Brain
CNS & Neurological Disorders - Drug Targets Inhibition of Glycogen Synthase Kinase-3 Reverses Tau Hyperphosphorylation Induced by Pin1 Down-Regulation
CNS & Neurological Disorders - Drug Targets Review: The Role of MOP and DOP Receptors in Treatment of Diarrheapredominant Irritable Bowel Syndrome
Mini-Reviews in Medicinal Chemistry microRNA, Cancer and Cancer Chemoprevention
Current Molecular Pharmacology Topotecan Is a Substrate for Multidrug Resistance Associated Protein 4
Current Drug Metabolism A Role for SNX1 in the Regulation of EGF-Dependent Phosphorylated EGFR Endocytosis Via the Early/Late Endocytic Pathway in a Gefitinib-Sensitive Human Lung Cancer Cells
Current Signal Transduction Therapy Chemical Origins of Isoform Selectivity in Histone Deacetylase Inhibitors
Current Pharmaceutical Design Counselling and Cognitive Behaviour Interventions Delivered to Reduce Psychological Morbidity and Improve Quality of Life in Gynaecological Cancer Patients: Recent Achievements
Current Women`s Health Reviews Recent Development in Indole Derivatives as Anticancer Agent: A Mechanistic Approach
Anti-Cancer Agents in Medicinal Chemistry Micro-RNA (miRNA): A Biomarker to Identify Novel Compounds in Drug Discovery and Delivery for Cancer Therapy
Current Drug Discovery Technologies